SCHEMBL2911248

SCHEMBL2911248

COc1ccc(Nc2ncc3cccc(C)c3n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
KDM4E B2RXH2 1/20 0.54
AURKA O14965 2/20 0.53
SYK P43405 1/20 0.53
ALDH1A1 P00352 2/20 0.53
CDK2 P24941 2/20 0.52
SRC P12931 2/20 0.52
CCNA2 P20248 1/20 0.52
TTK P33981 1/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
NPC1 O15118 1/20 0.50
LMNA P02545 1/20 0.50
MAPK1 P28482 1/20 0.50
RAB9A P51151 1/20 0.50
CDK5 Q00535 1/20 0.50
CDK5R1 Q15078 1/20 0.50
JAK2 O60674 1/20 0.49
JAK1 P23458 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29371294 0.84 MAPK10 (0.60) MAPTL3MBTL1AURKASYKALDH1A1
SCHEMBL18376750 0.84 MAPK10 (0.60) MAPTL3MBTL1AURKASYKALDH1A1
SCHEMBL12999378 0.83 AURKA (0.60) AURKASYKCDK2SRCCDK1
SCHEMBL12999380 0.83 JAK2 (0.52) MAPTCDK2JAK2JAK1TYK2
SCHEMBL2919611 0.80 L3MBTL1 (0.51) MAPTL3MBTL1KDM4EAURKASYK
SCHEMBL13057456 0.80 JAK2 (0.49) CDK2JAK2JAK1TYK2JAK3
SCHEMBL2917162 0.80 BRD4 (0.52) CDK2CCNA2NPC1RAB9AJAK2
SCHEMBL2913212 0.80 JAK2 (0.49) AURKASYKCDK2JAK2JAK1
SCHEMBL18377036 0.79 MAPK10 (0.55) MAPTAURKASYKALDH1A1CDK2
SCHEMBL29371938 0.79 MAPK10 (0.55) MAPTAURKASYKALDH1A1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K MAPT 4766/4885L3MBTL1 1868/4885KDM4E 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.